* FLAMEL TECHNOLOGIES *
1990 - Rhône-Alpes
Venissieux
(near Lyon)
www.flamel.com Delivery, Drugs
(also, Design, Devices)
Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action
Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry
Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry
info@flamel.com
Age: 19 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Willard (Stephen H.) [born 1960, ex-Biovail, Crédit Suisse, Gibson-Dunn-Crutch, Shearman & Sterling]
Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé]
Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé]
Fin.Dir.-CFO: Crouzet (Sian) [ex-McCormik, Ernst & Young]
BusDev: Franoux (Grégoire)
Strat.Dir.: Marlio (Charles) [ex-Baldwin Brothers]
Financers (Hist.): Public (Nasdaq) | Turnover (M€) : 23.8 (2008), 18.7 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .12 | Clinical trial (phase IIa) of IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection (beginning) | CLIN | [19 years] |
| 2009 .07 | Partnering research agreement with Baxter to formulate Longer Acting Forms of Blood Clotting Factors | R&D | [18 years] |
| 2009 .03 | Financing : € 2.9 Millions ($4 Million) from GlaxoSmithKline (GSK) as a milestone pursuant to the Micropump license agreement for Coreg CR | RFIN | [18 years] |
| 2007 .12 | Partnering research agreement with Merck Serono | R&D | [17 years] |
| 2006 .10 | Registration : FDA approval of Coreg (carvedilol S.R), licensed to GSK | MKTG | [16 years] |
| 2005 .06 | Nomination : Stephen H. Willard as CEO (from CFO in 2000), replacing founder Gérard Soula, after a coup by hedge funds | ORGN | [14 years] |
| 2003 .11 | Licensing-out of Basulin to BMS, with upfront payment of 18 M€ (20.0 MUS$) | LICOUT | [13 years] |
| 2003 .10 | Public offering (Nasdaq) : 56 M€ (62.1 MUS$) | PBO | [13 years] |
| 2002 .07 | Licensing-out of Augmentin delivery-improved to GSK, with upfront payment of 1.3 M€ | LICOUT | [11 years] |
| 2000 .03 | Round-financing : 12.8 M€, by Biotechnology Value Fund, Alta Biopharma, Chase Capital Partners | RFIN | [9 years] |
| 1999 .12 | Licensing-out of Basulin to Novo Nordisk, with upfront payment of 5 M€ and milestones of 37 M€ (rights re-acquired in 2002) | LICOUT | [9 years] |
| 1996 .12 | Listing on Nasdaq : 30 MUS$ (about 23.7 M€) | PBO | [6 years] |
| 1990 .08 | Company founded by Gérard Soula [CEO, ex-Rhône Poulenc R&D], Jean Deléage [Alta Partners, as CEO, Supélec] | ORGF | [0 year] | Actualisation / Updating: 04-Janv-2010 |
|
